# Nanjing Nuoling Biological Technology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nanjing-nuoling-biological-technology-co

- Industry: Medical Devices & Equipment
- Headquarters: Nanjing, China
- Website: www.novlead.com
- Total disclosed funding: $33M
- Latest round: Series C (Apr 15, 2025)
- Investors on record: 13

## About

Established in 2018 and based in Nanjing, China, Nanjing Nuoling Biological Technology Co., Ltd. is a medical device company that focuses on the research and development of novel medical devices. The company has set up R&D and production headquarters in Nanjing and a medical market center in Beijing. Wen Mao, the company's founder and CEO, has served as a senior executive at Abbott's U.S. headquarters for 6 years and the head of precision medicine for the World Economic Forum in Davos, China. In April 2025, it closed a series C funding.

The company's main products include portable NO therapy devices, NO wound gas therapy devices and exhaled NO detectors. Its products are used in diseases such as pulmonary hypertension, diabetic foot and COPD.

Nanjing Nuoling Biological Technology Co., Ltd. generates revenue by providing its innovative medical devices and related services to the healthcare industry.

The company will use the series C funding to expand the production capacity, commercialize and expand overseas of the company's portable NO inhalation therapy device.

## Funding rounds

- Series C, Apr 15, 2025 — Efung Capital, Triwise Capital, Dingxin Venture Capital, Hunan Xingxiang Investment Holding Group, Zhongshan Financial Investment Holdings, Yangzhou International Finance Investment
- Series B, Jun 20, 2023, $14M — Lilly Asia Ventures, CoStone Capital, 3E Bioventures Capital, Jianyuan Tianhua Investment Management (Beijing), Jinyuan Capital
- Series B, Nov 15, 2021, $19M — NLVC, Lilly Asia Ventures, 3E Bioventures Capital
- Series A, Jan 13, 2021 — NLVC, InnoMed Capital
- Angel, Dec 30, 2019 — InnoMed Capital

## Investors

- InnoMed Capital (https://capitalatlas.ai/funds/innomed-capital) — Angel, Series A
- NLVC (https://capitalatlas.ai/funds/nlvc) — Series A, Series B
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series B
- 3E Bioventures Capital (https://capitalatlas.ai/funds/3e-bioventures-capital) — Series B
- CoStone Capital (https://capitalatlas.ai/funds/costone-capital) — Series B
- Jianyuan Tianhua Investment Management (Beijing) — Series B
- Jinyuan Capital (https://capitalatlas.ai/funds/jinyuan-capital) — Series B
- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Series C
- Triwise Capital (https://capitalatlas.ai/funds/triwise-capital) — Series C
- Dingxin Venture Capital — Series C
- Hunan Xingxiang Investment Holding Group (https://capitalatlas.ai/funds/hunan-xingxiang-investment-holding-group) — Series C
- Zhongshan Financial Investment Holdings — Series C
- Yangzhou International Finance Investment — Series C